What changed: BRAF V600-mutant melanoma
Every dated change on the records linked to BRAF V600-mutant melanoma, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Approval6Regulatory2Trial result8Milestone8This record1
September 2026 · 1
2024 · 1
2021 · 2
2020 · 2
June 2018 · 2
2018 · 4
- 2018ApprovalEncorafenibEncorafenib approved in US
BRAF V600 melanoma with binimetinib
- 2018Trial resultCheckMate 204CheckMate 204 reported
Intracranial clinical benefit 57% and complete response 26% in the asymptomatic cohort.
- 2018Trial resultCOLUMBUSCOLUMBUS reported
PFS 14.
- 2018MilestoneCOLUMBUSCOLUMBUS: encorafenib-binimetinib approved
A milestone in how this cancer is treated.
2017 · 2
2015 · 2
2014 · 4
- 2014ApprovalTrametinibTrametinib approved in EU
BRAF V600 melanoma alone or with dabrafenib; later NSCLC and adjuvant melanoma
- 2014Trial resultcoBRIMcoBRIM reported
Median progression-free survival 12.
- 2014Trial resultCOMBI-dCOMBI-d reported
Median progression-free survival 11.
- 2014MilestoneCOMBI-dCOMBI-d and coBRIM: BRAF plus MEK doublets beat BRAF inhibitor alone
A milestone in how this cancer is treated.